MassMutual Private Wealth & Trust’s Monopar Therapeutics MNPR Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$239	Buy	+3	New	+$322	﹤0.01%	2319

Other funds holding MNPR

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Quadrature Capital London, United Kingdom $16.1B AUM 61.25% 1-Year Est. Return

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

MassMutual Private Wealth & Trust's MNPR Position: Q3 2026 in Review

MassMutual Private Wealth & Trust opened a new position in Monopar Therapeutics (MNPR) in Q3 2026: 3 shares worth $239. The stake represents ﹤0.01% of the portfolio and ranks #2319 among its holdings.

61 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.

MassMutual Private Wealth & Trust held 3 shares of Monopar Therapeutics worth $239 as of Q3 2026.
Monopar Therapeutics was a new MassMutual Private Wealth & Trust position in Q3 2026.
Monopar Therapeutics made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q3 2026, its #2319 holding.
61 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q3 2026, filed 5 Oct 2026.